<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278693</url>
  </required_header>
  <id_info>
    <org_study_id>ASD-1213-11</org_study_id>
    <nct_id>NCT01278693</nct_id>
  </id_info>
  <brief_title>Effect of Oral L-carnitine Supplement on Lipid Profile, Anemia, and Quality of Life of Patients</brief_title>
  <official_title>Study of Treatment of Dyslipidemia for Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine Effect of oral L-carnitine supplement on lipid
      profile, anemia, and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients under maintenance hemodialysis several factors reduce the body stored carnitine
      which in turn affected dyslipidemia, anemia, and general health in these patients. The
      investigators evaluated the effect of oral L-carnitine supplementation on lipid profiles,
      anemia, and quality of life in hemodialysis patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lipid profile</measure>
    <time_frame>at sixteen weeks after admission</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>anemia</measure>
    <time_frame>at sixteen weeks after admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at sixteen weeks after admission</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Complication of Hemodialysis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>it is as like as L-carnitine in shape</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-carnitine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>it is kind of supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-carnitine</intervention_name>
    <description>500 mg,twice daily, 16 weeks</description>
    <arm_group_label>L-carnitine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>500 mg,twice daily, 16 weeks.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        being in the age range of 18-75 having the history of at least 12 weeks of hemodialysis and
        at least three times a week and each session almost for four hours having serum
        triglyceride or total cholesterol concentration &gt;200 mg/dl or serum HDL concentration &gt;40
        mg/dl in the beginning of the study.

        Exclusion Criteria:

        taking carnitine supplement or the drug that interact with carnation lowering the seizure
        threshold in the last month being affected by liver function abnormalities, hypothyroidism,
        chronic infectious diseases (such as hepatitis), inflammatory diseases, CNS mass having the
        history of seizure.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahnaz Moradi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MD,research comittee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Noor university hospital</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.mui.ac.ir</url>
    <description>Isfahan university of medical sciences</description>
  </link>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2011</study_first_submitted>
  <study_first_submitted_qc>January 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2011</study_first_posted>
  <last_update_submitted>January 18, 2011</last_update_submitted>
  <last_update_submitted_qc>January 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alireza Yousefy, Associate Professor of Medical Education</name_title>
    <organization>Isfahan University of Medical Sciences</organization>
  </responsible_party>
  <keyword>Renal failure, hemodialysis, dyslipidemia, L-carnitine.</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

